Navigation Links
Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Date:9/24/2013

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Mr. Powell will be responsible for managing the company's legal affairs.  He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States."

Mr. Powell's experience spans two decades of leadership in the life sciences, most recently as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years, principally in healthcare and biotechnology.  He held positions of increasing responsibility for more than 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology.  Mr. Powell then served as SVP and General Counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
2. Eppendorf Video Features Dr Andrew Holts Work on Bioactive Leachates From Plastic Consumables
3. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
4. Robert Tungatt, Regulatory Compliance and Cold Chain Excellence Specialist Joins QuickSTAT
5. Chinese Leader in Genomics Joins Science Center's Port Community
6. Greg Plum Joins the SoundConnect Team
7. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
8. Dik Barsamian Joins the US HealthConnect Inc. Group of Companies as the New President of Its CME Enterprises
9. Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
10. Jeffrey Toobin Joins Gateway Public Schools for the 2013 Matters of the Mind Luncheon
11. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016 On Monday, the Department ... industry to share solutions for the Biometric Exit Program. ... and Border Protection (CBP), explains that CBP intends to ... the United States , in order ... defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):